Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Company Overview

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis. In March 2024, the U.S. Food and Drug Administration approved Rezdiffra, in combination with diet and exercise, for adults with noncirrhotic MASH and moderate to advanced liver fibrosis.

The company’s activities include the commercialization of Rezdiffra in the United States, as well as ongoing research and development related to MASH and associated liver conditions. Madrigal is led by Chief Executive Officer Paul A. Friedman, with Rebecca Taub serving as president and chief medical officer.

Key Stats

• Today's Range: $378.28 to $401.61
• 50-Day Range: $396.32 to $546.93
• 52-Week Range: $353.54 to $615.00
• Volume: 1.09 million shs
• Average Volume: 313,609 shs
• Market Capitalization: $9.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $706.87
• Consensus Rating: Moderate Buy

Madrigal Pharmaceuticals Stock Analysis - MarketRank™

Madrigal Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 94th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 13 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Madrigal Pharmaceuticals has a consensus price target of $706.87, representing about 76.9% upside from its current price of $399.63.

Amount of Analyst Coverage

Madrigal Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($3.78) to $6.79 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Madrigal Pharmaceuticals is -66.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Madrigal Pharmaceuticals is -66.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Madrigal Pharmaceuticals has a P/B Ratio of 15.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.53% of the float of Madrigal Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 7.24.

Change versus previous month

Short interest in Madrigal Pharmaceuticals has recently decreased by 8.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Madrigal Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Madrigal Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.69

News Sentiment

Madrigal Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 64 news articles for Madrigal Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

3 people have searched for MDGL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $28,010,688.00 in company stock, which represents 0.3034% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Madrigal Pharmaceuticals insiders have bought 399.47% more of their company's stock than they have sold. Specifically, they have bought $35,022,670.00 in company stock and sold $7,011,982.00 in company stock.

Percentage Held by Insiders

17.60% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/03/2026
• Today: 11/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MDGL
• CIK: 1157601
• Web: www.madrigalpharma.com
• Phone: (267) 824-2827
• Fax: 781-274-8228
• Employees: 915
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Madrigal Pharmaceuticals: $706.87
• High Price Target: $962.00
• Low Price Target: $542.00
• Potential Upside/Downside: +76.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 58.86
• P/E Growth: N/A
• Net Income: -$288.28 million
• Net Margins: -25.32%
• Pretax Margin: -25.32%
• Return on Equity: -56.65%
• Return on Assets: -25.53%

Debt

• Debt-to-Equity Ratio: 0.65
• Current Ratio: 3.20
• Quick Ratio: 2.94

Sales & Book Value

• Annual Sales: $958.40 million
• Price / Sales: 9.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $26.54 per share
• Price / Book: 15.06

Miscellaneous

• Outstanding Shares: 23,100,000
• Free Float: 19,142,000
• Market Cap: $9.23 billion
• Optionable: Optionable
• Beta: -0.98